TY - JOUR
T1 - Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction
T2 - a Danish nationwide study
AU - Christensen, Daniel Molager
AU - Schjerning, Anne-Marie
AU - Smedegaard, Laerke
AU - Charlot, Mette Gitz
AU - Ravn, Pauline B.
AU - Ruwald, Anne Christine
AU - Fosbol, Emil
AU - Kober, Lars
AU - Torp-Pedersen, Christian
AU - Schou, Morten
AU - Gerds, Thomas
AU - Gislason, Gunnar
AU - Sehested, Thomas S. G.
PY - 2023
Y1 - 2023
N2 - Aims Outcomes after myocardial infarction (MI) improved during recent decades alongside better risk factor management and implementation of guideline-recommended treatments. However, it is unknown whether this applies to stable patients who are event-free 1 year after MI. Methods and results Using nationwide Danish registries, we included all patients with first-time MI during 2000-17 who survived 1 year free from bleeding and cardiovascular events (n = 82 108, median age 64 years, 68.2% male). Follow-up started 1 year after MI and continued through January 2022. Crude risks of mortality, cardiovascular events, and bleeding were estimated in consecutive 3-year periods. Standardized risks were calculated with respect to the distribution of age, sex, comorbidities, and treatments in the latter period. Guideline-recommended treatment use increased during the study period: e.g. statins (68.6-92.5%) and percutaneous coronary intervention (23.9-68.2%). The crude 5-year risks of outcomes decreased (all P-trend
AB - Aims Outcomes after myocardial infarction (MI) improved during recent decades alongside better risk factor management and implementation of guideline-recommended treatments. However, it is unknown whether this applies to stable patients who are event-free 1 year after MI. Methods and results Using nationwide Danish registries, we included all patients with first-time MI during 2000-17 who survived 1 year free from bleeding and cardiovascular events (n = 82 108, median age 64 years, 68.2% male). Follow-up started 1 year after MI and continued through January 2022. Crude risks of mortality, cardiovascular events, and bleeding were estimated in consecutive 3-year periods. Standardized risks were calculated with respect to the distribution of age, sex, comorbidities, and treatments in the latter period. Guideline-recommended treatment use increased during the study period: e.g. statins (68.6-92.5%) and percutaneous coronary intervention (23.9-68.2%). The crude 5-year risks of outcomes decreased (all P-trend
KW - myocardial infarction stable
KW - Guidelines
KW - long-term risk
KW - Registry
KW - outcomes
KW - DUAL ANTIPLATELET THERAPY
KW - FIBRINOLYTIC THERAPY
KW - FOCUSED UPDATE
KW - TASK-FORCE
KW - 2017 ESC
KW - ELEVATION
KW - ASSOCIATION
KW - MANAGEMENT
KW - DISEASE
KW - RISK
U2 - 10.1093/eurheartj/ehac667
DO - 10.1093/eurheartj/ehac667
M3 - Journal article
C2 - 36433809
SN - 0195-668X
VL - 44
SP - 488
EP - 498
JO - European Heart Journal
JF - European Heart Journal
IS - 6
ER -